What Dimerix Biosciences does

Dimerix Limited (ASX:DXB) is a clinical-stage biopharmaceutical company headquartered in Fitzroy, Melbourne, Australia, developing therapeutics for inflammatory diseases with high unmet need. Its lead candidate, DMX-200 (repagermanium), is an oral chemokine receptor CCR2 blocker administered as an adjunct to standard angiotensin receptor blocker (ARB) therapy. DMX-200 is currently in the Phase 3 ACTION3 trial for Focal Segmental Glomerulosclerosis (FSGS), a rare progressive kidney disease affecting at least 210,000 people globally with no approved disease-modifying treatment. DMX-200 has received Orphan Drug Designation from both the FDA and EMA, with composition-of-matter patents extending to 2032 (potentially to 2042). The Phase 2a study showed 86% of patients achieving reduced proteinuria versus placebo and 29% achieving a greater than 40% reduction when added to background ARB therapy.

The company's discovery engine is Receptor-HIT (Heteromer Investigation Technology), a patented cell-based assay platform that identifies pairs of receptors (heteromers) with novel pharmacological behavior when ligands bind, applied to G-protein coupled receptor (GPCR) targets. The platform has yielded a second pre-clinical candidate, DMX-700, targeting orphan respiratory/renal disease. Receptor-HIT is also available for out-licensing to third parties.

Dimerix operates a capital-light, partner-led business model. It retains clinical development and IP responsibilities and out-licenses regional commercialization rights to partners that bear commercial risk. Current partners include Amicus Therapeutics (US, up to USD 560M in milestones plus royalties), Advanz Pharma (Europe, Canada, Australia, New Zealand), FUSO Pharmaceutical (Japan, ¥300M upfront), and Everest Medicines (Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines). Revenue today consists of upfront payments, development and regulatory milestones, and future royalties; the company is pre-commercial with last patient last dose in the Phase 3 ACTION3 trial expected in March 2028.

Name

Dimerix Biosciences

Legal name

Dimerix Limited

Website

https://dimerix.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Dimerix Biosciences (ASX:DXB) is a Melbourne-based clinical-stage biopharmaceutical company developing DMX-200, a CCR2 blocker in Phase 3 trials for the rare kidney disease FSGS, using its proprietary Receptor-HIT heteromer discovery platform and a global partner-led out-licensing model.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals (Rare Kidney Disease)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Clinical-stage biopharmaceuticals
• Rare kidney disease therapeutics
• Drug discovery platform
• Orphan drug development
• Inflammatory disease treatments

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Licensing and milestone payments: Dimerix generates revenue through upfront payments, development milestones, regulatory milestones, and sales royalties from regional licensing partners commercialising DMX-200 in their respective territories. Partners bear all commercial risk and costs in their regions.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Dimerix Biosciences is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory diseases, with its lead product DMX-200 (a CCR2 chemokine receptor blocker) in Phase 3 trials for Focal Segmental Glomerulosclerosis (FSGS) and a second candidate DMX-700 in pre-clinical development for orphan respiratory/renal disease. The company leverages its proprietary Receptor-HIT cell-based assay platform to identify heteromer receptor interactions and discover differentiated drugs targeting GPCRs, and operates a global out-licensing model where regional pharmaceutical partners commercialize DMX-200 in their territories.

Product overview

Dimerix is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. The company's lead product is DMX-200 (Phase 3, for Focal Segmental Glomerulosclerosis), with a second product candidate DMX-700 in pre-clinical development for orphan respiratory/renal disease. Dimerix operates its proprietary Receptor-HIT technology platform for drug discovery, which is available for global licensing. The company pursues a partnering strategy, having licensed DMX-200 rights to multiple global partners including Amicus Therapeutics (US), Advanz Pharma (Europe/Canada/Australia/NZ), FUSO Pharmaceutical (Japan), and Everest Medicines (Asia).

Differentiator

Problem solved

Functional benefit

Products and services

• DMX-200 (repagermanium) Chemokine receptor (CCR2) blocker administered as adjunct to standard angiotensin II type I receptor blocker (ARB) therapy. Currently in Phase 3 (ACTION3) clinical trials for Focal Segmental Glomerulosclerosis (FSGS), a rare progressive kidney disease.
• DMX-700 Pre-clinical drug candidate targeting orphan respiratory and renal diseases, designed to address unmet medical needs in inflammatory diseases affecting the respiratory and renal systems. Developed using the proprietary Receptor-HIT platform.
• Receptor-HIT Technology Platform Proprietary patented cell-based assay platform that identifies pairs of different receptors (heteromers) that function jointly when ligands bind. Applied to G-protein coupled receptors (GPCRs) for drug discovery across target validation, compound profiling, and candidate optimisation. Available for global licensing to third-party developers.

Quantifiable outcome

• 86% of patients demonstrated reduced proteinuria on DMX-200 versus placebo; 29% achieved >40% reduction in proteinuria in addition to background ARB therapy
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• Everest MedicinescoreChannel Partner/ Reseller/ Distributor · 16 June 2026Exclusive licensing agreement for DMX-200 covering Greater China, South Korea, and Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines). Everest assumes commercial risk and responsibilities for development and commercialization in these territories. Dimerix retains clinical development and IP responsibilities. Dimerix shares surged 21.2% to A$0.20 following the announcement.
• Amicus TherapeuticscoreChannel Partner/ Reseller/ DistributorSecured exclusive US rights for DMX-200 with potential deal value of up to USD 560 million in milestones and royalties. Amicus bears commercial risk in the US territory while Dimerix retains clinical development and IP responsibilities.
• Advanz PharmacoreChannel Partner/ Reseller/ DistributorAcquired exclusive rights for DMX-200 in Europe, Canada, Australia, and New Zealand. Advanz assumes commercialization responsibilities and commercial risk in these territories.
• FUSO PharmaceuticalcoreChannel Partner/ Reseller/ DistributorObtained Japan rights for DMX-200 with ¥300 million upfront payment. FUSO handles commercialization in Japan, reflecting the different market dynamics with lower upfront payments compared to the US.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Travere Therapeutics: Travere Therapeutics is the most directly comparable peer, developing sparsentan (FILSPARI) for FSGS and IgA nephropathy — the same rare kidney disease space as DMX-200. Both companies are running late-stage trials targeting proteinuria reduction in FSGS with potential first-in-class positioning.
• Chinook Therapeutics: Chinook Therapeutics (acquired by Novartis in 2023) developed atrasentan and other precision medicines for rare kidney diseases including IgA nephropathy. Directly comparable as a clinical-to-commercial rare kidney disease biotech with similar partnership-driven development model.
• Calliditas Therapeutics: Calliditas developed Nefecon (Tarpeyo), the first FDA-approved drug for IgA nephropathy, addressing proteinuria and kidney function decline in rare glomerular diseases. Highly comparable as a small-cap European/Australian-adjacent biotech that took a rare kidney disease therapy through Phase 3 and to approval via partnering.
• ChemoCentryx: ChemoCentryx (acquired by Amgen in 2022) developed tavneos, an oral complement inhibitor for ANCA-associated vasculitis, and was a pioneer in chemokine receptor (CCR1/CCR2/CCR5) drug discovery. Highly comparable to Dimerix for its focus on chemokine receptor pharmacology and small-molecule rare-disease therapeutics.
• BridgeBio Pharma: BridgeBio's affiliate companies developed infigratinib (and other rare disease programs) and acquired an FSGS program through its BridgeBio Pharma affiliate. Comparable as a clinical-to-commercial rare disease company with deep orphan drug expertise and a similar partnering-centric business model.

Emerging players

• Vera Therapeutics: Vera Therapeutics is developing atacicept for IgA nephropathy and other autoimmune kidney diseases, with Phase 3 data in a directly adjacent rare nephrology indication. Comparable as a clinical-stage rare kidney disease biotech with similar value-driving thesis around proteinuria reduction.
• Goldfinch Bio: Goldfinch Bio was a clinical-stage biotech focused on precision medicines for kidney diseases including FSGS, with a GPCR-adjacent mechanism focus. Comparable as an emerging rare kidney disease player pursuing similar proteinuria endpoints, though now largely inactive.

Broad incumbents

• Otsuka Pharmaceutical: Otsuka is a major incumbent in rare kidney disease through tolvaptan (Jynarque) for ADPKD and broader nephrology pipeline. Comparable as a large pharmaceutical player operating in the same orphan kidney disease space, providing both competitive context and a precedent for partner-led commercialization of rare renal therapies.
• Alexion / AstraZeneca Rare Disease: Alexion (now part of AstraZeneca) is the dominant commercial player in rare disease therapeutics including nephrology-adjacent indications. Comparable as a large established rare-disease commercial organization and potential strategic acquirer/licensee for orphan renal assets like DMX-200.

Others

• Amicus Therapeutics: Amicus is not a direct competitor but a licensee of DMX-200 for the US (up to $560M in milestones) and is also developing Galafold and other rare-disease therapies. Relevant as Dimerix's commercial partner and a bellwether for how the US FSGS market will be approached post-approval.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xx.com/dimerixltd
• LinkedInlinkedin.com/company/dimerix-bioscience

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dimerix Biosciences